trending Market Intelligence /marketintelligence/en/news-insights/trending/fs8najqic6p4r2kezgovfw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Homology Medicines prices IPO

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Homology Medicines prices IPO

Homology Medicines, Inc. priced its IPO of 9 million common shares at $16 per share.

The Bedford, Mass.-based genetic medicines company granted the underwriters an option to buy up to an additional 1,350,000 shares.

Homology's common stock is expected to start trading on the Nasdaq Global Select Market on March 28 under the ticker symbol FIXX.

Bank of America Merrill Lynch, Cowen and Evercore ISI are acting as joint book-running managers, while BTIG is acting as the lead manager for the offering.